GlobeNewswire Inc | Nov 23, 2020 08:00AM EST

November 23, 2020

CAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patients body, announced today that it participated in a pre-recorded fireside chat as part of the Piper Sandler 32ndAnnual Virtual Healthcare Conference, being held on December 1-3, 2020.

The pre-recorded presentation will be available to participants during the conference and on the Events page of the Investors & Media section of the Companys website www.cuebiopharma.com beginning today, November 23, 2020 at 10:00 a.m. EST. An archived version of the recording will be accessible for 90 days following the event.

AboutCue BiopharmaCue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patients body to transform the treatment of cancer, infectious diseases and autoimmune diseases. The companys proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) is designed to harness the bodys intrinsic immune system without the need for ex vivo manipulation.

Headquartered in Cambridge, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.

For more information, visitwww.cuebiopharma.com and follow us on Twitter https://twitter.com/CueBiopharma.

Investor ContactGeorge B. Zavoico, Ph.D.VP, Investor Relations & Corporate DevelopmentCue Biopharma, Inc.gzavoico@cuebio.com

Media ContactAlison ChenLifeSci Communicationsachen@lifescicomms.com